These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
96 related articles for article (PubMed ID: 15373718)
21. [Association between ribavirin plasma concentration and sustained virologic response in treatment of patients with genotype 1b chronic hepatitis C with pegylated interferon-α-2b and ribavirin]. Wang MR; Zhang X; Yang ZG; Li P; Gao L; Chen XH; Wang J; Xiong X; Wang SM; Geng JB; Hao KY; Xie F; Wang M; Zheng WK Zhonghua Gan Zang Bing Za Zhi; 2016 Mar; 24(3):175-80. PubMed ID: 27095759 [TBL] [Abstract][Full Text] [Related]
22. Ribavirin Concentrations Do Not Predict Sustained Virological Response in HIV/HCV-Coinfected Patients Treated with Ribavirin and Pegylated Interferon in the Swiss HIV Cohort Study. Kovari H; Russmann S; Ledergerber B; Müller D; Rotger M; Velli P; Cavassini M; Ambrosioni J; Bregenzer A; Stöckle M; Bernasconi E; Rauch A; Speck RF; PLoS One; 2015; 10(7):e0133879. PubMed ID: 26218843 [TBL] [Abstract][Full Text] [Related]
23. Interferon alfacon-1 and ribavirin versus interferon alpha-2b and ribavirin in the treatment of chronic hepatitis C. Sjogren MH; Sjogren R; Holtzmuller K; Winston B; Butterfield B; Drake S; Watts A; Howard R; Smith M Dig Dis Sci; 2005 Apr; 50(4):727-32. PubMed ID: 15844709 [TBL] [Abstract][Full Text] [Related]
24. Response-guided therapy for chronic hepatitis C virus infection in patients coinfected with HIV: a pilot trial. Van den Eynde E; Crespo M; Esteban JI; Jardi R; Ribera E; Carbonell J; Rodríguez-Frias F; Falco V; Curran A; Imaz A; Villar del Saz S; Ocaña I; Esteban R; Pahissa A Clin Infect Dis; 2009 Apr; 48(8):1152-9. PubMed ID: 19275492 [TBL] [Abstract][Full Text] [Related]
25. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. Chung RT; Andersen J; Volberding P; Robbins GK; Liu T; Sherman KE; Peters MG; Koziel MJ; Bhan AK; Alston B; Colquhoun D; Nevin T; Harb G; van der Horst C; N Engl J Med; 2004 Jul; 351(5):451-9. PubMed ID: 15282352 [TBL] [Abstract][Full Text] [Related]
26. Open, randomized, multicentre italian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV-coinfected patients on HAART. Cargnel A; Angeli E; Mainini A; Gubertini G; Giorgi R; Schiavini M; Duca P; Antivir Ther; 2005; 10(2):309-17. PubMed ID: 15865225 [TBL] [Abstract][Full Text] [Related]
27. Therapy of special HIV-associated diseases: HCV-HIV-co-infection and AIDS-related Kaposi's sarcoma - official satellite to the 7th European Conference on Clinical Aspects and Treatment of HIV-infection, October 23, 1999 in Lisbon, Portugal. Goebel FD; Jablonowski H Eur J Med Res; 1999 Dec; 4(12):507-13. PubMed ID: 10611054 [TBL] [Abstract][Full Text] [Related]
28. Current treatment for chronic hepatitis C virus/HIV-infected individuals: the role of pegylated interferon-alpha and ribavirin. Bhagani S Curr Opin HIV AIDS; 2011 Nov; 6(6):483-90. PubMed ID: 22001893 [TBL] [Abstract][Full Text] [Related]
29. Quantification of serum hepatitis C virus RNA with daily or standard interferon doses plus ribavirin in nonresponder patients with chronic hepatitis C. Buti M; Olive G; Stalgis C; Esteban R; Guardi J Dig Dis Sci; 2000 Apr; 45(4):685-9. PubMed ID: 10759235 [TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of combination therapy with interferon-alpha2b and ribavirin for chronic hepatitis C in HIV-infected patients. Landau A; Batisse D; Duong Van Huyen JP; Piketty C; Bloch F; Pialoux G; Belec L; Petite JP; Weiss L; Kazatchkine MD AIDS; 2000 May; 14(7):839-44. PubMed ID: 10839592 [TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of pegylated interferon plus ribavirin in HIV and hepatitis C virus-coinfected patients with advanced immunosuppression. Mira JA; Gutiérrez-Valencia A; Gil Ide L; Merino D; Rivero A; Ríos-Villegas MJ; Delgado M; González-Serrano M; Collado A; Torres-Tortosa M; Omar M; López-Ruz MA; Macías J; Arponen S; Pineda JA Clin Infect Dis; 2009 Oct; 49(8):e84-91. PubMed ID: 19772388 [TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of peg-IFN alfa-2a with ribavirin for the treatment of HCV/HIV coinfected patients who failed previous IFN based therapy. Rodríguez-Torres M; Rodríguez-Orengo JF; Ríos-Bedoya CF; Fernández-Carbia A; González-Lassalle E; Salgado-Mercado R; Marxuach-Cuétara AM J Clin Virol; 2007 Jan; 38(1):32-8. PubMed ID: 17064957 [TBL] [Abstract][Full Text] [Related]
33. Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir. Vispo E; Barreiro P; Pineda JA; Mira JA; Maida I; Martín-Carbonero L; Rodríguez-Nóvoa S; Santos I; López-Cortes LF; Merino D; Rivero A; Soriano V Antivir Ther; 2008; 13(3):429-37. PubMed ID: 18572756 [TBL] [Abstract][Full Text] [Related]
34. Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: an early report. Zylberberg H; Benhamou Y; Lagneaux JL; Landau A; Chaix ML; Fontaine H; Bochet M; Poynard T; Katlama C; Pialoux G; Bréchot C; Pol S Gut; 2000 Nov; 47(5):694-7. PubMed ID: 11034587 [TBL] [Abstract][Full Text] [Related]
35. Efficacy of early treatment of acute hepatitis C infection with pegylated interferon and ribavirin in HIV-infected patients. Dominguez S; Ghosn J; Valantin MA; Schruniger A; Simon A; Bonnard P; Caumes E; Pialoux G; Benhamou Y; Thibault V; Katlama C AIDS; 2006 May; 20(8):1157-61. PubMed ID: 16691067 [TBL] [Abstract][Full Text] [Related]
36. Lead-in treatment with interferon-β/ribavirin may modify the early hepatitis C virus dynamics in pegylated interferon alpha-2b/ribavirin combination for chronic hepatitis C patients with the IL28B minor genotype. Itokawa N; Atsukawa M; Tsubota A; Kondo C; Hashimoto S; Fukuda T; Matsushita Y; Kidokoro H; Kobayashi T; Narahara Y; Nakatsuka K; Kanazawa H; Iwakiri K; Sakamoto C J Gastroenterol Hepatol; 2013 Mar; 28(3):443-9. PubMed ID: 23173698 [TBL] [Abstract][Full Text] [Related]
37. Simeprevir (TMC435) with pegylated interferon/ribavirin in patients coinfected with HCV genotype 1 and HIV-1: a phase 3 study. Dieterich D; Rockstroh JK; Orkin C; Gutiérrez F; Klein MB; Reynes J; Shukla U; Jenkins A; Lenz O; Ouwerkerk-Mahadevan S; Peeters M; De La Rosa G; Tambuyzer L; Jessner W Clin Infect Dis; 2014 Dec; 59(11):1579-87. PubMed ID: 25192745 [TBL] [Abstract][Full Text] [Related]
38. Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study. Escudero A; Rodríguez F; Serra MA; Del Olmo JA; Montes F; Rodrigo JM J Gastroenterol Hepatol; 2008 Jun; 23(6):861-6. PubMed ID: 18422960 [TBL] [Abstract][Full Text] [Related]
39. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Poynard T; Marcellin P; Lee SS; Niederau C; Minuk GS; Ideo G; Bain V; Heathcote J; Zeuzem S; Trepo C; Albrecht J Lancet; 1998 Oct; 352(9138):1426-32. PubMed ID: 9807989 [TBL] [Abstract][Full Text] [Related]
40. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. Laguno M; Murillas J; Blanco JL; Martínez E; Miquel R; Sánchez-Tapias JM; Bargallo X; García-Criado A; de Lazzari E; Larrousse M; León A; Loncá M; Milinkovic A; Gatell JM; Mallolas J AIDS; 2004 Sep; 18(13):F27-36. PubMed ID: 15316335 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]